A 28-day, randomised, double-blind, placebo-controlled study to assess the safety, tolerability, anti-inflammatory effect and steady-state pharmacokinetics of SB-681323 7.5 mg per day in patients with chronic obstructive pulmonary disease
Latest Information Update: 04 Jul 2023
At a glance
- Drugs Dilmapimod (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 16 Sep 2009 Tolerabilty, pharmacodyamics and efficacy results reported at the 19th Annual Congress of the European Respiratory Society.
- 02 Nov 2005 New trial record.